

Mutlu Hizal

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/70584/mutlu-hizal-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17
papers

47
citations

4
h-index

6
g-index

21
ext. papers

69
ext. citations

2.7
avg, IF

1.69
L-index

#	Paper	IF	Citations
17	Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database. <i>Future Oncology</i> , 2021 , 17, 4861-4869	3.6	1
16	The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 1	4.9	0
15	The effect of EML4-ALK break-apart ratio on crizotinib outcomes in non-small cell lung cancer harboring EML4-ALK rearrangement. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021 , 147, 2637-2643	4.9	0
14	Neutrophil-lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study). <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 1583-1589	1.7	1
13	A historical turning point for the treatment of advanced renal cell carcinoma: inhibition of immune checkpoint. <i>Current Medical Research and Opinion</i> , 2020 , 36, 625-635	2.5	3
12	The association of clinicopathologic features and peripheral blood parameters with high PD-L1 expression in non-small cell lung cancer. <i>Tuberkuloz Ve Toraks</i> , 2020 , 68, 118-125	0.8	1
11	The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 1110-1116	1.7	10
10	An update on immunotherapy options for urothelial cancer. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1265-1274	5.4	9
9	Do tyrosine kinase inhibitors lose favor in treatment of first-line metastatic renal cell carcinoma?. <i>Future Oncology</i> , 2019 , 15, 925-927	3.6	
8	Prognostic effect of red cell distribution width-to-platelet ratio in colorectal cancer according to tumor stage and localization. <i>Journal of Cancer Research and Therapeutics</i> , 2019 , 15, 54-60	1.2	6
7	Optimal regimen for treatment-naive hormone receptor-positive HER-2 negative metastatic breast cancer. <i>Future Oncology</i> , 2019 , 15, 105-107	3.6	
6	Expanding treatment options for resectable gastric cancer: Is it a countdown for radiotherapy?. <i>Jbuon</i> , 2019 , 24, 1367-1370	1	1
5	Evaluation of dynamic serum thiol/disulfide homeostasis in locally advanced and metastatic gastric cancer. <i>Journal of Oncological Science</i> , 2018 , 4, 1-4	0.4	4
4	Mutational status of lung cancer patients and survival outcomes for patients with limited brain metastases. <i>Journal of B U on</i> , 2018 , 23, 156		
3	The current status of adjuvant treatment for high-risk renal cell carcinoma. <i>Future Oncology</i> , 2017 , 13, 2017-2020	3.6	
2	Do all aromatase inhibitors have similar efficacy and safety?. <i>Future Oncology</i> , 2017 , 13, 1673-1676	3.6	1
1	Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?. <i>Clinical Rheumatology</i> , 2015 , 34, 795-8	3.9	8

